BioSpace

FDA clears Pfizer, Arvinas’ novel breast cancer therapy despite mixed data

Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...
Fierce Pharma

FDA hands Pfizer, Arvinas’ Veppanu early approval for breast cancer subtype

Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...

US FDA approves Pfizer, Arvinas' breast cancer drug

May 1 (Reuters) - The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' breast cancer drug for ...
STAT

Pharmalittle: We’re reading about the FDA speeding up trials, a Supreme Court hearing on ‘skinny labels,’ and more

The FDA announced efforts to make clinical trials more efficient, starting by reviewing data in real time from trials ...